ストックスクリーナーアプリを入手
11.64
1.04%
0.12
前日終値:
$11.52
開ける：
$11.53
24時間の取引高:
871.25K
Relative Volume:
0.52
時価総額：
$3.66B
収益：
$2.68B
当期純損益:
$-184.45M
株価収益率:
-17.11
EPS:
-0.6805
ネットキャッシュフロー:
$229.23M
1週間 パフォーマンス:
+2.37%
1か月 パフォーマンス:
+19.75%
6か月 パフォーマンス:
+58.37%
1年 パフォーマンス:
+29.33%
1日の値動き範囲:
$11.44
$11.71
1週間の範囲:
$11.38
$12.12
52週間の値動き範囲:
$6.685
$12.12
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
11.64 | 3.62B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-02-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal Pharmaceuticals (AMRX): Valuation Perspective After FDA Greenlight for First Generic Omnipaque and Raised Guidance - Yahoo Finance
Is Amneal Pharmaceuticals Inc. stock oversold or undervaluedStop Loss & High Conviction Investment Ideas - newser.com
Is Amneal Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Drop Watch & Daily Profit Focused Stock Screening - newser.com
FDA Approves First Generic Omnipaque: Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock - Investing.com India
What analyst consensus says on Amneal Pharmaceuticals Inc. stockStock Surge & Momentum Based Trading Signals - newser.com
FDA approves Amneal’s generic iohexol injection for imaging procedures By Investing.com - Investing.com Australia
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point - simplywall.st
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)’s Price Target To $13 Following Q3 Earnings Beat - MSN
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat - Finviz
Multi asset correlation models including Amneal Pharmaceuticals Inc.Portfolio Update Summary & Advanced Swing Trade Entry Plans - newser.com
Is Amneal Pharmaceuticals Inc. stock ready for a breakout2025 Top Gainers & Community Verified Trade Signals - newser.com
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones index2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Amneal gets FDA nod for Iohexol Injection (AMRX:NASDAQ) - Seeking Alpha
Amneal Receives U.S. FDA Approval for Iohexol Injection - The Manila Times
Amneal (NASDAQ: AMRX) expects to launch first generic Omnipaque iohexol in Q1 2026 - Stock Titan
Published on: 2025-11-13 05:47:52 - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum playPortfolio Gains Report & Daily Risk Controlled Trade Plans - newser.com
Real time breakdown of Amneal Pharmaceuticals Inc. stock performanceEarnings Overview Report & Weekly High Potential Stock Alerts - newser.com
Amneal Pharmaceuticals stock reaches 52-week high at 11.89 USD By Investing.com - Investing.com Philippines
Is Amneal Pharmaceuticals Inc. stock resilient to inflationTrade Volume Summary & Long-Term Growth Plans - newser.com
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know - The Globe and Mail
Amneal Pharmaceuticals stock reaches 52-week high at 11.89 USD - Investing.com
Amneal Pharmaceuticals outlook revised to positive by S&P Global By Investing.com - Investing.com Philippines
Amneal Pharmaceuticals outlook revised to positive by S&P Global - Investing.com Philippines
Amgen Says Dr. Reddy’s, Amneal Biosimilars Infringe Patents - Bloomberg Law News
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
2.58%
4.09%
大文字化:
|
ボリューム (24 時間):